Fibrinolysin

• 

  Subject Areas on Research

  • A colorimetric assay for releasable plasminogen activator. 
  • A nonantigenic covalent streptokinase-polyethylene glycol complex with plasminogen activator function. 
  • ATP-regulated activity of the plasmin-streptokinase complex: a novel mechanism involving phosphorylation of streptokinase. 
  • Activation of human plasminogen by urokinase. Partial characterization of a pre-activation peptide. 
  • Analysis of the plasma elimination kinetics and conformational stabilities of native, proteinase-complexed, and reactive site cleaved serpins: comparison of alpha 1-proteinase inhibitor, alpha 1-antichymotrypsin, antithrombin III, alpha 2-antiplasmin, angiotensinogen, and ovalbumin. 
  • Antifibrinolytic therapy: new data and new concepts. 
  • Application of a plasmin generation assay to define pharmacodynamic effects of tranexamic acid in women undergoing cesarean delivery. 
  • Assessment of retinal morphology with spectral and time domain OCT in the phase III trials of enzymatic vitreolysis. 
  • Association between anatomical resolution and functional outcomes in the mivi-trust studies using ocriplasmin to treat symptomatic vitreomacular adhesion/vitreomacular traction, including when associated with macular hole. 
  • Axonal regrowth after spinal cord injury via chondroitinase and the tissue plasminogen activator (tPA)/plasmin system. 
  • BASELINE CHARACTERISTICS OF VITREOMACULAR TRACTION PROGRESSING TO FULL-THICKNESS MACULAR OR LAMELLAR HOLES IN THE PHASE III TRIALS OF ENZYMATIC VITREOLYSIS. 
  • Binding and endocytosis of alpha 2-macroglobulin-plasmin complexes. 
  • Carbon monoxide releasing molecule-2 enhances α2-antiplasmin activity. 
  • Catabolic pathways for streptokinase, plasmin, and streptokinase activator complex in mice. In vivo reaction of plasminogen activator with alpha 2-macroglobulin. 
  • Catabolism of streptokinase and polyethylene glycol-streptokinase: evidence for transport of intact forms through the biliary system in the mouse. 
  • Cell migration through defined, synthetic ECM analogs. 
  • Characterization of alpha 2-macroglobulin-plasmin complexes: complete subunit cleavage alters receptor recognition in vivo and in vitro. 
  • Characterization of prorenin activation using a synthetic peptide substrate. 
  • Characterization of vitreoretinal interface disorders using OCT in the interventional phase 3 trials of ocriplasmin. 
  • Circulating biomarkers for abdominal aortic aneurysm: what did we learn in the last decade? 
  • Conformation and protease binding activity of binary and ternary human alpha 2-macroglobulin-protease complexes. 
  • Degradation of von Willebrand factor in patients with acquired clinical conditions in which there is heightened proteolysis. 
  • EVALUATION OF FULL-FIELD ELECTRORETINOGRAM REDUCTIONS AFTER OCRIPLASMIN TREATMENT: Results of the OASIS Trial ERG Substudy. 
  • Effect of methylamine and plasmin on the conformation of human alpha 2-macroglobulin as revealed by differential scanning calorimetric analysis. 
  • Efficacy of intravitreal ocriplasmin for treatment of vitreomacular adhesion: subgroup analyses from two randomized trials. 
  • Electron microscopic identification of exposed plasmin epitopes in alpha 2-macroglobulin-plasmin complex using monoclonal antibody-colloidal gold adducts. 
  • Elevated plasma homocysteine leads to alterations in fibrin clot structure and stability: implications for the mechanism of thrombosis in hyperhomocysteinemia. 
  • Epitope mapping of the von Willebrand factor subunit distinguishes fragments present in normal and type IIA von Willebrand disease from those generated by plasmin. 
  • Fibrinolysis and fibrinogenolysis by Val442-plasmin. 
  • High dose factor VIIa improves clot structure and stability in a model of haemophilia B. 
  • In vitro preparation of nonenzymatically glucosylated human transferrin, alpha 2-macroglobulin, and fibrinogen with preservation of function. 
  • In vitro studies of acantholysis of keratinocytes induced by pemphigus antibody. 
  • Inflammatory, hemostatic, and other novel biomarkers for diabetic retinopathy: the multi-ethnic study of atherosclerosis. 
  • Inhibition of platelet-derived growth factor-BB-induced fibroblast proliferation by plasmin-activated alpha 2-macroglobulin is mediated via an alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein-dependent mechanism. 
  • Ionic modulation of the effects of heparin on plasminogen activation by tissue plasminogen activator: the effects of ionic strength, divalent cations, and chloride. 
  • Keratinocyte urokinase-type plasminogen activator is secreted as a single chain precursor. 
  • Lipoprotein (a) promotes plasmin inhibition by alpha 2-antiplasmin. 
  • Lipoprotein (a) regulates plasmin generation and inhibition. 
  • Lipoprotein (a): purification and kinetic analysis. 
  • Mechanism of activation of human plasminogen by the activator complex, streptokinase-plasmin. 
  • Mechanism of ancrod anticoagulation. A direct proteolytic effect on fibrin. 
  • Model of alpha 2-macroglobulin structure and function. 
  • Plasmin binding to the plasminogen receptor enhances catalytic efficiency and activates the receptor for subsequent ligand binding. 
  • Plasmin-mediated proteolysis of vascular endothelial cell heparin releasable tissue factor pathway inhibitor. 
  • Poly(ethylene glycol) hydrogels conjugated with a collagenase-sensitive fluorogenic substrate to visualize collagenase activity during three-dimensional cell migration. 
  • Proteolysis of von Willebrand factor after thrombolytic therapy in patients with acute myocardial infarction. 
  • Purification and characterization of human alpha 2-macroglobulin conformational variants by non-ideal high performance size-exclusion chromatography. 
  • Purification and some properties of the Glu- and Lys-human plasmin heavy chains. 
  • Reaction of human alpha 2-macroglobulin half-molecules with plasmin as a probe of protease binding site structure. 
  • Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma. 
  • Specificity of alpha 2-macroglobulin covalent cross-linking for the active domain of proteinases. 
  • Subfoveal Lucency after Treatment of Vitreomacular Traction without Macular Hole in the Phase 3 Trials of Ocriplasmin Vitreolysis. 
  • Substructure of human von Willebrand factor. 
  • Successful treatment of acute vascular insufficiency in a hand by intra-arterial fibrinolysin, heparin, and reserpine. Case report. 
  • Symmetry of the inhibitory unit of human alpha 2-macroglobulin. 
  • The effect of plasmin on the subunit structure of human fibrin. 
  • The effect of plasmin on the subunit structure of human fibrinogen. 
  • The effect of substituted laminin A chain-derived peptides on the conformation and activation kinetics of plasminogen. 
  • The role of inter-alpha-trypsin inhibitor and other proteinase inhibitors in the plasma clearance of neutrophil elastase and plasmin. 
  • The temperature-dependent reaction between alpha 2-macroglobulin and streptokinase-plasmin(ogen) complex. 
  • The voltage-dependent anion channel (VDAC) binds tissue-type plasminogen activator and promotes activation of plasminogen on the cell surface. 
  • Why is lipoprotein(a) relevant to thrombosis? 
  • tPA-mediated generation of plasmin is catalyzed by the proteoglycan NG2.